Beam Therapeutics Inc.
NASDAQ:BEAMBiotechnology
+$0.48 today
- Market cap
- $2.17B
- Beta
- 2.20
- P/E (TTM)
- -52.3
- EPS (TTM)
- -$0.63
Volume 4.86M
Average 2.11M
BEAM Weighted Avg Shares (Diluted)
Average shares outstanding including dilutive securities, used to calculate diluted EPS.
Beam Therapeutics Inc.NASDAQ: BEAM
Weighted Avg Shares (Diluted) · Q2 FY2026 · quarter ended Jun 2026
Weighted avg shares (diluted) grows, but more slowly than its trailing trend
Q2 FY2026 weighted avg shares (diluted) of 104.33M shares rose 2.3% year over year, behind the +17.0% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 1.0% from the prior quarter. Over 3 fiscal years it compounded at +12.2% a year.
Context
- Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +2.3% toward the trailing-twelve-month pace of +17.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares (Diluted) history
Shares · from the income statement
- Latest · FY2025
- 98.91M USD
- Year-over-year change
- +20.2%
- 4-year CAGR
- +11.4%
| Period | Period end | Weighted Avg Shares (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 98.91M | +20.2% |
| FY2024 | 2024-12-31 | 82.31M | +6.7% |
| FY2023 | 2023-12-31 | 77.15M | +10.2% |
| FY2022 | 2022-12-31 | 70.02M | +9.0% |
| FY2021 | 2021-12-31 | 64.23M | — |
Weighted Avg Shares (Diluted) vs competitors
How BEAM compares with its peers on the latest reported figures
- BEAM's LTM Jun 2026 weighted avg shares (diluted) of 103.77M shares is the 4th highest of the 9 companies compared; the peer median is 97.59M shares.
- Its year-over-year change of +17.0% is the 2nd highest of 9, against a peer median of +8.8%.
- Over three fiscal years its annual growth of +12.2% compares with a peer median of +13.7%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | 225.47M | +9.3% | +15.5% | |
| LTM Mar 2026 | 119.09M | +1.0% | +7.1% | |
| LTM Mar 2026 | 110.2M | +9.3% | +12.1% | |
| LTM Jun 2026 | 103.77M | +17.0% | +12.2% | |
| LTM Mar 2026 | 100.38M | +2.9% | +30.1% | |
| LTM Sep 2026 | 94.81M | +8.4% | +5.0% | |
| LTM Mar 2026 | 94.18M | +3.6% | +15.4% | |
| LTM Mar 2026 | 90.28M | +9.3% | +8.9% | |
| LTM Mar 2026 | 12.13M | +60.9% | +63.6% | |
| Peer median (excluding BEAM) | 97.59M | +8.8% | +13.7% | |
Competitors are the stored peer set for BEAM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 51.84M | 60.92M | 377.71M | 63.52M | 139.74M |
| Cost of Revenue | 232.13M | 311.59M | 0 | 367.56M | 22.29M |
| Gross Profit | (180.29M) | (250.67M) | 377.71M | (304.04M) | 117.45M |
| Gross Margin | -347.8% | -411.5% | 100.0% | -478.7% | 84.0% |
| Research & Development | 387.09M | 311.59M | 437.38M | 367.56M | 409.62M |
| Selling, General & Admin | 57.22M | 87.81M | 116.81M | 111.53M | 113.82M |
| Operating Expenses | 212.18M | 87.81M | 554.19M | 111.53M | 501.14M |
| Depreciation & Amortization | 7.45M | 14.15M | 20.01M | 21.93M | 22.29M |
| EBITDA | (230.06M) | (271.53M) | (111.15M) | (354.78M) | (13.97M) |
| EBITDA Margin | -443.8% | -445.7% | -29.4% | -558.5% | -10.0% |
| Operating Income | (392.47M) | (338.48M) | (176.49M) | (415.57M) | (383.69M) |
| Operating Margin | -757.0% | -555.6% | -46.7% | -654.3% | -274.6% |
| Interest Income | 0 | 15.3M | 46.68M | 49.09M | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 43.73M |
| Other Income / Expenses | 21.83M | 52.8M | 45.32M | 38.87M | 303.7M |
| Income Before Tax | (370.64M) | (285.68M) | (131.16M) | (376.7M) | (79.99M) |
| Pre-Tax Margin | -714.9% | -468.9% | -34.7% | -593.1% | -57.2% |
| Income Tax Expense | 0 | 3.41M | 1.37M | 39K | 0 |
| Net Income | (370.64M) | (289.09M) | (132.53M) | (376.74M) | (79.99M) |
| Net Margin | -714.9% | -474.5% | -35.1% | -593.1% | -57.2% |
| EPS (Basic) | (5.77) | (4.13) | (1.72) | (4.58) | (0.81) |
| EPS (Diluted) | (5.77) | (4.13) | (1.72) | (4.58) | (0.81) |
| Weighted Avg Shares | 64.23M | 70.02M | 77.15M | 82.31M | 98.91M |
| Weighted Avg Shares (Diluted) | 64.23M | 70.02M | 77.15M | 82.31M | 98.91M |
Beam Therapeutics Inc.
NASDAQ:BEAM
Intrinsic Alpha fair value
Locked
Current Price
$21.01
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.